HB 137, Rep. Quinn
This bill is intended to compel individuals who overdose to obtain a screening and referral for addiction treatment by making immunity from prosecution contingent upon their doing so within 30 days of receiving emergency services for the overdose.
Contact (phone or email):
Hon. Stan Saylor
Chair, House Appropriations Committee
Hon. Matthew Bradford
Democratic Chair, House Appropriations Committee
Please review the members of the House Appropriations Committee – if you live or operate a program in the district of any of these members, please contact that member as well.
When: By December 16, 2019
Why: HB 137 has significant potential to have serious unintended consequences that may ultimately result in deaths, avoidance or delay of medical care, and overburdening an already stressed system of care for Pennsylvanians struggling with the disease of addiction.
If passed, this bill is very likely to exacerbate these fears and further inhibit or delay calls for assistance in a life and death situation when seconds count.
The Department of Drug and Alcohol Programs (DDAP) is accepting applications from SCAs who shall expand or create a collaborative between local law enforcement, treatment professionals, and recovery support providers to establish a diversion program. Active and engaged relationships with the local District Attorney, identified local police departments, Opioid Use Disorder (OUD) treatment providers, and Certified Recovery Specialists (CRS) shall be foundational to such an initiative. Rather than experiencing legal consequences for an OUD, individuals shall receive treatment and support services for the underlying cause of the arrest.
Reminder: Questions can be submitted via email through tomorrow, November 20, 2019 by 5:00 pm. Applications are due by December 5.
DDAP is accepting applications from SCAs who shall expand or create a collaborative between local law enforcement, treatment professionals, and recovery support providers to establish a diversion program. Active and engaged relationships with the local District Attorney, identified local police departments, Opioid Use Disorder (OUD) treatment providers, and Certified Recovery Specialists (CRS) shall be foundational to such an initiative. Rather than experiencing legal consequences for an OUD, individuals shall receive treatment and support services for the underlying cause of the arrest. Applications are due by December 5.
Learn more on the Funding Opportunities page.
November 5, 2019
Contact your lawmakers today and urge them to cosponsor the Comprehensive Addiction Resources Emergency (CARE) Act (S.1365, H.R.2569). Tackling our nation’s addiction crisis starts with a commitment to treatment and recovery services.
The bill recognizes the scope of the crisis and the resources necessary to truly affect change. The bill provides state and local governments with $100 billion in federal funding over ten years to expand access to evidence-based treatment and recovery support services. The bill also recognizes the importance of workforce development by authorizing $500 million in workforce development funding for professionals treating substance use disorders.
NAADAC is proud to champion this legislation and was thrilled to support its introduction. We ask now that you help us advocate for the resources needed to build an SUD workforce that meets the demands of the crisis.
Contact your lawmakers TODAY: Please call the U.S. Capitol directly at 202-224-3121 and urge your Representative/Senator to cosponsor the Comprehensive Addiction Resources Emergency (CARE) Act (S.1365, H.R.2569). Click here to find your U.S. Representative and click here to find your U.S. Senators.
What You Need to Say: “As an addiction professional and constituent, I strongly urge you to cosponsor the Comprehensive Addiction Resources Emergency (CARE) Act (S.1365/H.R.2569).
The CARE Act seeks to address the ongoing addiction crisis by providing state and local governments with dedicated resources for SUD treatment and recovery services and for building a workforce that meets the challenges of this ongoing crisis.”
Thank you for your dedication to support those in need of addiction and mental health prevention, intervention, treatment, and recovery support!
Yesterday (November 4), the Centers for Medicare & Medicaid Services (CMS) sent a letter to Opioid Treatment Programs (OTPs) and State Opioid Treatment Authorities (SOTAs) regarding Medicare’s coverage for opioid use disorder treatment services furnished by OTPs.
Additionally, CMS will host a call on Tuesday, November 12 to help OTPs understand the new benefit and how to enroll in Medicare. Please share the following announcement with your members and encourage them to attend.
Opioid Treatment Programs: Enrolling in Medicare
Tuesday, November 12, 2019 from 3:00 pm – 4:30 pm
Register here for Medicare Learning Network events.
Starting January 1, 2020, under the CY 2020 Physician Fee Schedule final rule, CMS will pay Opioid Treatment Programs (OTPs) through bundled payments for opioid use disorder treatment services for people with Medicare Part B.
During this call, learn about the new benefit, the Medicare program, and how to enroll. For more information, visit the OTP web page.
Target Audience: Fully certified and accredited OTPs and related staff, as well as interested stakeholders.
If members have further questions, please contact RCPA Drug & Alcohol Division Director Kristen Houser.
The Human Services Committee of the Pennsylvania House of Representatives has scheduled a public hearing on SB 675 related to the Licensing of Prescribers of Suboxone. The hearing will be on Tuesday, November 19 at 9:00 am in Room 60, East Wing.
The list of individuals who will testify is being finalized. It is our understanding that the goal of the hearing is to find a compromise between support and opposition of the bill. Individuals may submit requests to testify or submit additional comments directly to the Committee Chairs and copy to the Executive Directors of the Human Services Committee; both Erin Raub and Ashley McCahan.
If you have any further questions, please contact RCPA Drug and Alcohol Division Director, Kristen Houser.